Merck + Co., Inc.

Abbott Laboratories Corporation

Richard B Toupence

Thomas F Walsh

Michael R Schrimpf

Jerome F Daanen

Kevin B Sippy

William H Bunnelle

Karin Rosemarie Tietje

Jianguo Ji

Anwer Basha

Arthur A Patchett

Kenneth J Fitch

Gregory D Berger

Joel Peter Berger

David E Moller

Mark D Leibowitz

William J Greenlee

Prasun K Chakravarty

Mark T Goulet

Michael J Dart

Jennifer M Frost

Scott William Bagley

John S Debenham

Ralph A Rivero

Nancy J Kevin

Daljit S Dhanoa

Douglas J Pettibone

David L Williams

Thomas W Doebber

Theodore P Broten

Jennifer M Pace

John T Olson

Jay M Matthews

Richard L Tolman

Matthew J Wyvratt

Shrenik K Shah

Paul E Finke

Donald W Graham

Feroze Ujjainwalla

Jinlong Jiang

Soumya P Sahoo

Jonathan R Young

James R Tata

Michael D Meyer

Alan D Adams

Xenia Beebe Searle

Christina B Madsen-Duggan

Robert Joseph Devita

Eric E Allen

Derek J Von Langen

Keith Brian Ryther

Conrad Santini

Gerard R Kieczykowski

Laura C Meurer

Anthony B Jones

Daniela Barlocco Cristina

Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

Diazabicyclic central nervous system active agents

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted 2,3-diphenyl pyridines

Compounds of formula I: or pharmaceutically acceptable salts thereof, are useful for controlling synaptic transmission in mammals.

Diazabicyclic CNS active agents

Compounds of formula (I) are novel CNS active agents that are useful for treating pain and for treating other disorders associated with the cholinergic system.

Azabicyclic compounds are central nervous system active agents

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted furo[2,3-b]pyridine derivatives

Antagonists of gonadotropin releasing hormone

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.

Benzisoxazole-derived antidiabetic compounds

Method of treating diabetes and related disease states

Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.

Phenoxyphenylacetic acid derivatives

Biphenyl compounds useful or endothelin antagonists

Growing community of inventors

South Plainfield, NJ, United States of America

Richard B Toupence